PATENT CLAIM ANALYSIS

Application Number: 16130801
Application Type: Utility
Filing Date: 2018-09
Publication Date: 2019-04
Patent Classification: ["544", "350000"]

Abstract:
The present invention is directed to imidazo[1,2-a]pyrazine derivatives which are LSD1 inhibitors useful in the treatment of diseases such as cancer.

Claim (Index 78):
The method of  claim 59 , wherein R B  is methyl, chloro, trifluoromethyl, piperidinyl, methoxy, ethyl, 2-oxopyrrolidinyl, methyl(tetrahydrofuran-2-ylmethyl)amino, fluoro, 2-oxo-1,3-oxazolidinyl, amino, cyano, hydroxymethyl, (4-(methylsulfonyl)piperazin-1-ylmethyl, hydroxy, morpholin-4-ylmethyl, (CH 3 O)(C\u2550O)N(CH 3 ), (CH 3 O)(C\u2550O)N(CH 3 )-methyl, 1-hydroxyethyl, cyanomethyl, 3-methyl-2-oxoimidazolidinyl or dimethylamino.

Metadata:
- Claim Count in Document: 2.0
- Percentile: 97.0
- Lexical Diversity: 1.0
- Patent Class: 544.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['14795466', '15613361', '15610015', '14795536', '16038924']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8294192716103677
- 35 USC 102 Novelty (BERT): 0.6610262821383559
- Combined Prediction Score: 0.8125799726631665
- Mean Citation Score: 619.088486
- Max Citation Score: 655.64526
- Similarity Product: 623.2219344175099

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test